[Fundamental and clinical studies on tobramycin by intravenous drip infusion (author's transl)].
Fundamental and clinical studies on tobramycin (TOB) by intravenous drip infusion were carried out, and following results were observed. 1) Serum concentration of TOB. TOB was administered 1.5 mg/kg or 3.0 mg/kg by intramuscular or intravenous drip infusion method to 16 pediatric patients. In 1.5 mg/kg dose, the mean peak serum concentration were 3.9 mcg/ml at the 1/4 approximately 1/2 hour after administration by intramuscular method, 4.9 mcg/ml at the 1/2 hour after administration by 30 minutes intravenous drip infusion, 6.4 mcg/ml at 1 hour by 60 minutes intravenous drip infusion method. The half lives (T 1/2) of TOB in those methods, were 1.48, 1.42, 1.26 hours, respectively. In 3.0 mg/kg dose schedule by 30 or 60 minutes intravenous drip infusion method, the mean peak serum concentrations were 11.5 mcg/ml, 8.0 mcg/ml at the end of infusion, respectively. Those of the T 1/2 were 1.54, 1.24 hours. Pharmacokinetic parameters of TOB were following results. The ranges of Vd (apparent volume of distribution), K10 (elimination constant (hr-1)), T 1/2 were 0.20 approximately 0.34 L, 0.63 approximately 1.37 hr-1, 1.20 approximately 2.07 hrs., respectively and there was no significant difference in the serum concentrations and in the pharmacokinetic parameters. 2) Clinical results. Eight patients including 1 purulent cervical lymphadenitis, 4 acute pyelonephritis, 2 bronchopneumonia, 1 septicemia were treated with TOB 1.5 mg/kg or 3.0 mg/kg twice a day, by intravenous drip infusion for 6 approximately 15 days. Clinical effects were excellent in 3 cases, good in 4 cases and poor in 1 case. Efficacy rate was 87.5%. No side effects were observed.
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007263:Infusions, Parenteral; D007700:Kinetics; D008297:Male; D008954:Models, Biological; D014031:Tobramycin / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014031:Tobramycin